PMC:7205724 / 22500-22807 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"788","span":{"begin":103,"end":106},"obj":"Gene"},{"id":"789","span":{"begin":286,"end":289},"obj":"Gene"},{"id":"791","span":{"begin":79,"end":87},"obj":"Species"},{"id":"793","span":{"begin":44,"end":55},"obj":"Chemical"},{"id":"794","span":{"begin":143,"end":154},"obj":"Chemical"},{"id":"795","span":{"begin":220,"end":226},"obj":"Chemical"}],"attributes":[{"id":"A788","pred":"tao:has_database_id","subj":"788","obj":"Gene:3569"},{"id":"A789","pred":"tao:has_database_id","subj":"789","obj":"Gene:1401"},{"id":"A791","pred":"tao:has_database_id","subj":"791","obj":"Tax:9606"},{"id":"A793","pred":"tao:has_database_id","subj":"793","obj":"MESH:C502936"},{"id":"A794","pred":"tao:has_database_id","subj":"794","obj":"MESH:C502936"},{"id":"A795","pred":"tao:has_database_id","subj":"795","obj":"MESH:D010100"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T164","span":{"begin":260,"end":270},"obj":"Body_part"}],"attributes":[{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T268","span":{"begin":96,"end":97},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T269","span":{"begin":130,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0008426"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T171","span":{"begin":143,"end":154},"obj":"Chemical"},{"id":"T172","span":{"begin":220,"end":226},"obj":"Chemical"}],"attributes":[{"id":"A171","pred":"chebi_id","subj":"T171","obj":"http://purl.obolibrary.org/obo/CHEBI_64360"},{"id":"A172","pred":"chebi_id","subj":"T172","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-MedDRA","denotations":[{"id":"T22","span":{"begin":220,"end":255},"obj":"http://purl.bioontology.org/ontology/MEDDRA/10022891"}],"attributes":[{"id":"A22","pred":"meddra_id","subj":"T22","obj":"http://purl.bioontology.org/ontology/MEDDRA/10033322"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-PD-IDO","denotations":[{"id":"T102","span":{"begin":196,"end":204},"obj":"http://purl.obolibrary.org/obo/OGMS_0000020"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-CHEBI","denotations":[{"id":"T110","span":{"begin":220,"end":226},"obj":"Chemical"}],"attributes":[{"id":"A110","pred":"chebi_id","subj":"T110","obj":"http://purl.obolibrary.org/obo/CHEBI_25805"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T184","span":{"begin":79,"end":297},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"793","span":{"begin":44,"end":55},"obj":"Chemical"},{"id":"791","span":{"begin":79,"end":87},"obj":"Species"},{"id":"788","span":{"begin":103,"end":106},"obj":"Gene"},{"id":"794","span":{"begin":143,"end":154},"obj":"Chemical"},{"id":"795","span":{"begin":220,"end":226},"obj":"Chemical"},{"id":"789","span":{"begin":286,"end":289},"obj":"Gene"}],"attributes":[{"id":"A793","pred":"pubann:denotes","subj":"793","obj":"MESH:C502936"},{"id":"A791","pred":"pubann:denotes","subj":"791","obj":"Tax:9606"},{"id":"A788","pred":"pubann:denotes","subj":"788","obj":"Gene:3569"},{"id":"A794","pred":"pubann:denotes","subj":"794","obj":"MESH:C502936"},{"id":"A795","pred":"pubann:denotes","subj":"795","obj":"MESH:D010100"},{"id":"A789","pred":"pubann:denotes","subj":"789","obj":"Gene:1401"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T2161","span":{"begin":103,"end":106},"obj":"Protein"},{"id":"T2205","span":{"begin":286,"end":289},"obj":"Protein"}],"attributes":[{"id":"A2161","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9XT80"},{"id":"A2162","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU4"},{"id":"A2163","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU3"},{"id":"A2164","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9UCU2"},{"id":"A2165","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9MZR1"},{"id":"A2166","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q9MYZ7"},{"id":"A2167","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q95KN6"},{"id":"A2168","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q95181"},{"id":"A2169","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q90YI0"},{"id":"A2170","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q8MKH0"},{"id":"A2171","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q8BN26"},{"id":"A2172","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q865X6"},{"id":"A2173","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q865W7"},{"id":"A2174","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q6V919"},{"id":"A2175","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q6L6X6"},{"id":"A2176","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q5I6E3"},{"id":"A2177","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q3UCQ0"},{"id":"A2178","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q2MH06"},{"id":"A2179","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28819"},{"id":"A2180","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28747"},{"id":"A2181","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q28319"},{"id":"A2182","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q25BC2"},{"id":"A2183","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q0PW36"},{"id":"A2184","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q0GGL7"},{"id":"A2185","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/Q08DT2"},{"id":"A2186","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P79341"},{"id":"A2187","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P51494"},{"id":"A2188","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P46650"},{"id":"A2189","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41693"},{"id":"A2190","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41683"},{"id":"A2191","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P41323"},{"id":"A2192","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P29455"},{"id":"A2193","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P26893"},{"id":"A2194","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P26892"},{"id":"A2195","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P20607"},{"id":"A2196","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P08505"},{"id":"A2197","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/P05231"},{"id":"A2198","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O46568"},{"id":"A2199","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O35736"},{"id":"A2200","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/O19007"},{"id":"A2201","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/B6CKP4"},{"id":"A2202","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A9QWQ9"},{"id":"A2203","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A3FBE9"},{"id":"A2204","pred":"uniprot_id","subj":"T2161","obj":"https://www.uniprot.org/uniprot/A0S0B0"},{"id":"A2205","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q5U0J2"},{"id":"A2206","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q07203"},{"id":"A2207","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/Q01687"},{"id":"A2208","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P97315"},{"id":"A2209","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P67967"},{"id":"A2210","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P67966"},{"id":"A2211","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P47875"},{"id":"A2212","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P32965"},{"id":"A2213","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P21291"},{"id":"A2214","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/P08462"},{"id":"A2215","pred":"uniprot_id","subj":"T2205","obj":"https://www.uniprot.org/uniprot/A8K268"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-Enju","denotations":[{"id":"T44653","span":{"begin":3,"end":5},"obj":"CC"},{"id":"T55941","span":{"begin":6,"end":14},"obj":"JJ"},{"id":"T85453","span":{"begin":15,"end":23},"obj":"VBD"},{"id":"T98598","span":{"begin":24,"end":27},"obj":"CD"},{"id":"T96881","span":{"begin":28,"end":30},"obj":"CC"},{"id":"T24534","span":{"begin":31,"end":34},"obj":"CD"},{"id":"T70238","span":{"begin":35,"end":40},"obj":"NNS"},{"id":"T20616","span":{"begin":41,"end":43},"obj":"IN"},{"id":"T68912","span":{"begin":44,"end":55},"obj":"NNP"},{"id":"T98192","span":{"begin":56,"end":60},"obj":"CC"},{"id":"T20706","span":{"begin":61,"end":69},"obj":"JJ"},{"id":"T58005","span":{"begin":70,"end":77},"obj":"NN"},{"id":"T96625","span":{"begin":79,"end":87},"obj":"NNS"},{"id":"T75572","span":{"begin":88,"end":91},"obj":"WP"},{"id":"T31917","span":{"begin":92,"end":95},"obj":"VBD"},{"id":"T15301","span":{"begin":96,"end":97},"obj":"DT"},{"id":"T24848","span":{"begin":98,"end":102},"obj":"JJ"},{"id":"T84688","span":{"begin":103,"end":106},"obj":"NN"},{"id":"T96963","span":{"begin":107,"end":112},"obj":"NN"},{"id":"T6930","span":{"begin":113,"end":115},"obj":"IN"},{"id":"T90933","span":{"begin":116,"end":120},"obj":"JJR"},{"id":"T81944","span":{"begin":121,"end":125},"obj":"IN"},{"id":"T75581","span":{"begin":126,"end":135},"obj":"NN"},{"id":"T64021","span":{"begin":136,"end":142},"obj":"IN"},{"id":"T9387","span":{"begin":143,"end":154},"obj":"NN"},{"id":"T84664","span":{"begin":155,"end":164},"obj":"NN"},{"id":"T18203","span":{"begin":165,"end":171},"obj":"VBD"},{"id":"T60803","span":{"begin":172,"end":183},"obj":"NN"},{"id":"T44490","span":{"begin":184,"end":186},"obj":"IN"},{"id":"T81402","span":{"begin":187,"end":195},"obj":"JJ"},{"id":"T14228","span":{"begin":196,"end":204},"obj":"NNS"},{"id":"T94537","span":{"begin":205,"end":208},"obj":"CC"},{"id":"T83697","span":{"begin":209,"end":219},"obj":"JJ"},{"id":"T13978","span":{"begin":220,"end":226},"obj":"NN"},{"id":"T35808","span":{"begin":227,"end":237},"obj":"NN"},{"id":"T34900","span":{"begin":238,"end":241},"obj":"CC"},{"id":"T75964","span":{"begin":242,"end":255},"obj":"NN"},{"id":"T84268","span":{"begin":256,"end":259},"obj":"IN"},{"id":"T65028","span":{"begin":260,"end":270},"obj":"NN"},{"id":"T34390","span":{"begin":271,"end":281},"obj":"NN"},{"id":"T96610","span":{"begin":282,"end":285},"obj":"CC"},{"id":"T30755","span":{"begin":286,"end":289},"obj":"NN"},{"id":"T63070","span":{"begin":290,"end":296},"obj":"NNS"},{"id":"T31791","span":{"begin":298,"end":302},"obj":"RB"},{"id":"T31152","span":{"begin":302,"end":303},"obj":"-COMMA-"}],"relations":[{"id":"R81194","pred":"arg2Of","subj":"T55941","obj":"T44653"},{"id":"R42123","pred":"arg2Of","subj":"T70238","obj":"T85453"},{"id":"R67132","pred":"arg1Of","subj":"T70238","obj":"T98598"},{"id":"R74424","pred":"arg1Of","subj":"T98598","obj":"T96881"},{"id":"R53734","pred":"arg2Of","subj":"T24534","obj":"T96881"},{"id":"R5731","pred":"arg1Of","subj":"T70238","obj":"T24534"},{"id":"R65601","pred":"arg1Of","subj":"T70238","obj":"T20616"},{"id":"R56743","pred":"arg2Of","subj":"T98192","obj":"T20616"},{"id":"R89899","pred":"arg1Of","subj":"T68912","obj":"T98192"},{"id":"R61440","pred":"arg2Of","subj":"T58005","obj":"T98192"},{"id":"R97353","pred":"arg1Of","subj":"T58005","obj":"T20706"},{"id":"R37793","pred":"arg1Of","subj":"T96625","obj":"T75572"},{"id":"R91228","pred":"arg1Of","subj":"T96625","obj":"T31917"},{"id":"R53068","pred":"arg2Of","subj":"T96963","obj":"T31917"},{"id":"R75826","pred":"arg1Of","subj":"T96963","obj":"T15301"},{"id":"R53187","pred":"arg1Of","subj":"T96963","obj":"T24848"},{"id":"R88261","pred":"arg1Of","subj":"T96963","obj":"T84688"},{"id":"R96088","pred":"arg1Of","subj":"T96963","obj":"T6930"},{"id":"R5373","pred":"arg2Of","subj":"T90933","obj":"T6930"},{"id":"R57258","pred":"arg1Of","subj":"T90933","obj":"T81944"},{"id":"R94369","pred":"arg2Of","subj":"T75581","obj":"T81944"},{"id":"R45661","pred":"arg1Of","subj":"T90933","obj":"T64021"},{"id":"R79916","pred":"arg2Of","subj":"T84664","obj":"T64021"},{"id":"R78642","pred":"arg1Of","subj":"T84664","obj":"T9387"},{"id":"R8185","pred":"arg1Of","subj":"T96625","obj":"T18203"},{"id":"R51850","pred":"arg2Of","subj":"T94537","obj":"T18203"},{"id":"R12091","pred":"arg1Of","subj":"T60803","obj":"T44490"},{"id":"R66809","pred":"arg2Of","subj":"T14228","obj":"T44490"},{"id":"R61551","pred":"arg1Of","subj":"T14228","obj":"T81402"},{"id":"R5554","pred":"arg1Of","subj":"T60803","obj":"T94537"},{"id":"R21619","pred":"arg2Of","subj":"T34900","obj":"T94537"},{"id":"R92393","pred":"arg1Of","subj":"T35808","obj":"T83697"},{"id":"R24887","pred":"arg1Of","subj":"T35808","obj":"T13978"},{"id":"R90774","pred":"arg1Of","subj":"T35808","obj":"T34900"},{"id":"R67692","pred":"arg2Of","subj":"T75964","obj":"T34900"},{"id":"R62752","pred":"arg1Of","subj":"T34900","obj":"T84268"},{"id":"R8244","pred":"arg2Of","subj":"T63070","obj":"T84268"},{"id":"R10896","pred":"arg1Of","subj":"T63070","obj":"T65028"},{"id":"R57903","pred":"arg1Of","subj":"T63070","obj":"T34390"},{"id":"R97168","pred":"arg1Of","subj":"T34390","obj":"T96610"},{"id":"R13130","pred":"arg2Of","subj":"T30755","obj":"T96610"},{"id":"R88299","pred":"arg1Of","subj":"T63070","obj":"T30755"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sample-PD-FMA","denotations":[{"id":"T164","span":{"begin":260,"end":270},"obj":"Body_part"}],"attributes":[{"id":"A164","pred":"fma_id","subj":"T164","obj":"http://purl.org/sig/ont/fma/fma62863"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}

{"project":"LitCovid-sentences","denotations":[{"id":"T184","span":{"begin":79,"end":297},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"re or critical received one or two doses of Tocilizumab plus standard therapy. Patients who had a mean IL6 level of more than 100 pg/ml before tocilizumab treatment showed improvement in clinical symptoms and peripheral oxygen saturation and normalization for lymphocyte proportion and CRP levels. Also, lun"}